Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma.
Lajmanovich A, Ribeyron JB, Florin A, Fournier A, Pasquier MA, Duley S, Chauvet M, Plumas J, Bonnefoix T, Gressin R, Leroux D, Callanan MB. Lajmanovich A, et al. Among authors: gressin r. Exp Cell Res. 2009 Nov 15;315(19):3281-93. doi: 10.1016/j.yexcr.2009.09.008. Epub 2009 Sep 12. Exp Cell Res. 2009. PMID: 19751723
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Chaubard S, Marouf A, Lavergne D, Lemonnier F, Rossignol J, Clavert A, Gressin R, Cartron G, Waultier-Rascalou A, Vargaftig J, Salles G, Bachy E, Ghesquières H, Tournilhac O, Chauchet A, Le Gouill S, Damaj G, Fornecker LM, Sibon D, Obéric L, Michot JM, Gaulard P, Hermine O, Couronné L, Jaccard A. Chaubard S, et al. Among authors: gressin r. Br J Haematol. 2023 May;201(4):673-681. doi: 10.1111/bjh.18689. Epub 2023 Feb 17. Br J Haematol. 2023. PMID: 36799516
The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity.
Desmots F, Rossille D, Roussel M, Pangault C, Louarn L, De Saint Jore M, Le Gouill S, Bouabdallah K, Delwail V, Gressin R, Cornillon J, Damaj G, Maisonneuve H, Damotte D, Kraeber-Bodere F, Lamy T, Parrens MC, Milpied N, Fest T. Desmots F, et al. Among authors: gressin r. Clin Cancer Res. 2023 Jun 13;29(12):2280-2290. doi: 10.1158/1078-0432.CCR-22-2964. Clin Cancer Res. 2023. PMID: 37014666 Free article. Clinical Trial.
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Al Tabaa Y, Casasnovas RO, Baillet C, Bachy E, Nicolas-Virelizier E, Schiano De Colella JM, Bailly C, Kanoun S, Guidez S, Gyan E, Gressin R, Morineau N, Ysebaert L, Le Gouill S, Tilly H, Houot R, Morschhauser F, Cartron G, Herbaux C. Al Tabaa Y, et al. Among authors: gressin r. Blood Adv. 2023 Jul 25;7(14):3735-3738. doi: 10.1182/bloodadvances.2023009911. Blood Adv. 2023. PMID: 37067945 Free PMC article. No abstract available.
Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.
Dufour J, Choquet S, Hoang-Xuan K, Schmitt A, Ahle G, Houot R, Taillandier L, Gressin R, Casasnovas O, Marolleau JP, Tamburini J, Serrier C, Perez E, Paillassa J, Gyan E, Chauchet A, Ursu R, Kas A, Soussain C, Houillier C. Dufour J, et al. Among authors: gressin r. Ann Hematol. 2023 May;102(5):1159-1169. doi: 10.1007/s00277-023-05108-6. Epub 2023 Mar 29. Ann Hematol. 2023. PMID: 36991231
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°. Cheminant M, et al. Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17. Gut. 2019. PMID: 30448772
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Stathis A, Pirosa MC, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas RO, Cartron G, Devizzi L, Haioun C, Liberati AM, Houot R, Merli M, Pietrantuono G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S, Zucca E, Thieblemont C. Stathis A, et al. Among authors: gressin r. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918. Online ahead of print. Haematologica. 2024. PMID: 38385243 Free article.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Ghesquières H, Cherblanc F, Belot A, Micon S, Bouabdallah KK, Esnault C, Fornecker LM, Thokagevistk K, Bonjour M, Bijou F, Haioun C, Morineau N, Ysebaert L, Damaj G, Tessoulin B, Guidez S, Morschhauser F, Thiéblemont C, Chauchet A, Gressin R, Jardin F, Fruchart C, Labouré G, Fouillet L, Lionne-Huyghe P, Bonnet A, Lebras L, Amorim S, Leyronnas C, Olivier G, Guieze R, Houot R, Launay V, Drénou B, Fitoussi O, Detourmignies L, Abraham J, Soussain C, Lachenal F, Pica GM, Fogarty P, Cony-Makhoul P, Bernier A, Le Guyader-Peyrou S, Monnereau A, Boissard F, Rossi C, Camus V. Ghesquières H, et al. Among authors: gressin r. Blood Adv. 2024 Jan 23;8(2):296-308. doi: 10.1182/bloodadvances.2023010798. Blood Adv. 2024. PMID: 37874913 Free PMC article.
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.
Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J. Manches O, et al. Among authors: gressin r. Blood. 2003 Feb 1;101(3):949-54. doi: 10.1182/blood-2002-02-0469. Epub 2002 Oct 3. Blood. 2003. PMID: 12393572 Free article.
129 results